Darian Ratliff, MD
Internal Medicine · Hazard, KYNPI 1760484216
Payments from drug & device makers
Across 302 payments — averaging $14.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$731
- Johnson & Johnson$456
- AbbVie$436
- Pfizer$429
- Sanofi-aventis U.S. LLC$388
- Lilly USA, LLC$357
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,42599%
- Education$601%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 29 | $731 |
| Johnson & Johnson | 36 | $456 |
| AbbVie(2 entities) | 35 | $436 |
| Pfizer | 33 | $429 |
| Sanofi-aventis U.S. LLC | 32 | $388 |
| Lilly USA, LLC | 29 | $357 |
| Novo Nordisk | 23 | $296 |
| Amgen(2 entities) | 4 | $178 |
| Boehringer Ingelheim | 8 | $125 |
| Amarin Pharma, Inc. | 10 | $122 |
| Novartis | 8 | $111 |
| Merck | 7 | $94 |
| GSK | 6 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $80 |
| Daiichi Sankyo Inc. | 5 | $74 |
| Biohaven Pharmaceuticals, Inc. | 4 | $68 |
| Grifols USA, LLC | 3 | $62 |
| Esperion Therapeutics, Inc. | 4 | $61 |
| Bayer | 3 | $48 |
| Gilead | 2 | $41 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $39 |
| Portola Pharmaceuticals, LLC | 1 | $34 |
| Nestle Healthcare Nutrition Inc. | 2 | $29 |
| Exact Sciences | 2 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Tris Pharma Inc | 1 | $18 |
| Shield Therapeutics Inc | 1 | $18 |
| La Jolla Pharmaceutical Company | 1 | $16 |
| Radius Health, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,485 in reported general payments places this provider in the 85th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 181 | $162,911 |
| OzempicSemaglutide | 143 | $149,283 |
| FarxigaDapagliflozin Propanediol | 108 | $111,080 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 88 | $75,841 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 87 | $68,144 |
| MounjaroTirzepatide | 56 | $63,068 |
| JardianceEmpagliflozin | 68 | $61,224 |
| Xigduo XrDapaglifloz Propaned/Metformin | 74 | $59,688 |
| TrulicityDulaglutide | 38 | $58,412 |
| Tresiba Flextouch U-200Insulin Degludec | 45 | $44,536 |
| VascepaIcosapent Ethyl | 92 | $42,878 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 78 | $38,104 |
| XareltoRivaroxaban | 41 | $36,252 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 28 | $32,655 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 46 | $30,293 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $429 | $177,899195 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $731 | $158,794186 claims |
| Novo NordiskOzempic | $296 | $149,283143 claims |
| Lilly USA, LLCMounjaro, Trulicity | $357 | $121,48094 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Jentadueto | $125 | $118,311150 claims |
| MerckJanumet Xr, Janumet, Januvia | $94 | $98,593115 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $388 | $37,47446 claims |
| Johnson & JohnsonXarelto | $456 | $36,25241 claims |
| AbbVieLinzess | $436 | $28,70439 claims |
| NovartisEntresto | $111 | $10,57213 claims |
| GSKTrelegy Ellipta | $87 | $9,51316 claims |
| BayerKerendia | $48 | $8,96814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Hazard
- John JonesHazard$63K
- Mark AdamsLondon$15.4M
- Matthew WenkerErlanger$12.8M
- Jason ChesneyLouisville$6.3M
- Neil FarrisLexington$3M
- David JohnsonOwensboro$787K
- Hollis ClarkMurray$780K
- Fares KhaterWhitesburg$412K
- Christopher PhillipsPaducah$315K
- Cynthia Bowman-StroudPaducah$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.